Targeting FLT3 and KIT Mutations in AML with Midostaurin: Implications for Clinicians and Pharmacists.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2019, v. 9, n. 3, p. 150
- By:
- Publication type:
- Article
Works matching IS 21641153 AND DT 2019 AND VI 9 AND IP 3
Results: 7
1
2
Anticoagulant Use in Patients with Ibrutinib-Related Atrial Fibrillation - AUTHORS’ RESPONSE.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2019, v. 9, n. 3, p. 148
- By:
- Publication type:
- Article
3
Anticoagulant Use in Patients with Ibrutinib-Related Atrial Fibrillation.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2019, v. 9, n. 3, p. 148
- By:
- Publication type:
- Article
4
Review of Biosimilars and Their Potential Use in Oncology Treatment and Supportive Care in the United States.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2019, v. 9, n. 3, p. 133
- By:
- Publication type:
- Article
5
Thromboprophylaxis in Patients with Newly Diagnosed Multiple Myeloma Who Received Lenalidomide-Based Regimens.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2019, v. 9, n. 3, p. 127
- By:
- Publication type:
- Article
6
Correction.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2019, v. 9, n. 3, p. 126
- Publication type:
- Article
7
Comparing Granulocyte Colony-Stimulating Factors Prescribing Practices versus Guideline Recommendations in a Large Community Cancer Center.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2019, v. 9, n. 3, p. 121
- By:
- Publication type:
- Article